Extracellular Vesicles Isolated From Bone Marrow Mesenchymal Stem Cells Induce An Anti-Inflammatory Phenotype In Microglia Exposed To Human Abeta 1-42
2016-01-01 Elia, Ca; Marchetti, S; Losurdo, M; Saccomano, A; Filipello, F; Rasile, M; Tamborini, M; Matteoli, M; Coco, S
A Neuro-Vascular Unit in vitro model for drug screening of Blood Brain Barrier permeability and Immune Cells Trafficking
2023-01-01 Lauranzano, E; Ravanelli, Mm; Rasile, M; Molteni, R; Faggiani, E; Liberatore, G; Pardi, R; Orazio, En; Matteoli, M
Baseline markers of inflammation and outcome with Nivolumab in pretreated Non Small Cell Lung Cancers: a retrospective study.
2018-01-01 Russo, A; Battaglia, A; Provazza, G; Lo Certo, G; Ricciardi, Grr; Picciotto, M; Scimone, A; Toscano, G; Adamo, V; Franchina, T.
31 Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients
2020-01-01 De Miguel Perez, D; Russo, A; Gunasekaran, M; Cardona, A; Lapidus, R; Cooper, B; Et, Al.
117P Family history of cancer and improved outcomes with first-line immunotherapy in NSCLC patients.
2021-01-01 Cortellini, A; Buti, S; Di Maio, M; Giusti, R; Nigro, O; Cantini, L; Bria, E; Grossi, F; Torniai, M; De Tursi, M; Citarella, F; Mazzoni, F; Gelibter, A; Macerelli, M; Migliorino, Mr; Russo, A; Addeo, A; Porzio, G; Ficorella, C; Pinato, Dj.
New strategies to overcome BRAF resistance in melanoma: extended BRAF or BRAF/MEK inhibition? A pooled analysis.
2017-01-01 Franchina, T; Raiti, F; Moretti, G; Zanghì, M; Ricciardi, Grr; Russo, A; Franchina, V; Adamo, V.
Immune-Oncology Gene Expression Profiles allow lung cancer patients' stratification and identification of responders to immunotherapy.
2019-01-01 Tabbò, F; Annaratone, L; Nocifora, A; Vignale, C; Carnio, S; Metovic, J; Veneziano, F; Scodes, S; Russo, A; Franchina, T; Sini, C; Coco, S; Garlatti, P; Scotti, V; Adamo, V; Boccardo, S; Grossi, F; Cappuzzo, F; Papotti, M; Righi, L; Passiglia, F; Novello, S.
Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study.
2020-01-01 Nigro, O; Pinotti, G; Giusti, R; Filetti, M; De Galitiis, F; Di Pietro, Fr; Bersanelli, M; Lazzarin, A; Catino, A; Pizzutillo, P; Russano, M; Torniai, M; Ricciuti, B; Russo, A; Tudini, M; Bolzacchini, E; Di Marino, P; Rijavec, E; Vallini, I; Ficorella, C; Cortellini, A.
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance
2013-01-01 Franchina, T; Russo, A; Picciotto, M; Scimone, A; Berenato, R; Noto, L; Schifano, S; Adamo, V.
Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis.
2018-01-01 Giuffrida, D; Chillari, F; Blanco, G; Russo, A; Franchina, T; Puliafito, I; Prestifilippo, A; Battaglia, A; Castorina, L; Adamo, V.
PO-063: Extracellular vesicle miRNAs and autophagic CTCs: Predictive and prognostic biomarkers in radiotherapy treated NSCLC patients.
2021-01-01 De Miguel Perez, D; Tejada, Rg; Russo, A; Ortega, Fg; Martínez-Única, A; Gunasekaran, M; Lorente, Ja; Exposito, J; Fernandez, Mjs; Rolfo, C
The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis
2015-01-01 Bronte, G; Franchina, T; Alù, M; Sortino, G; Celesia, C; Passiglia, F; Savio, G; Laudani, A; Russo, A; Picone, A; Rizzo, S; Blasi, L; Adamo, V; Russo, A.
Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non small cell lung cancer (NSCLC)
2019-01-01 Russo, A; Franchina, T; Ricciardi, G; Battaglia, A; Schifano, S; Schifilliti, M; Scimone, A; Toscano, G; Zanghì, M; Adamo, V.
The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lung cancer patients: Findings from a retrospective analysis.
2015-01-01 Bronte, G; Franchina, T; Alù, M; Sortino, G; Celesia, C; Passiglia, F; Savio, G; Laudani, A; Russo, A; Picone, A; Rizzo, S; Blasi, L; Adamo, V; Russo, A.
Baseline Absolute Neutrophil Count (ANC), derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Platelet-to-Lymphocyte Ratio (PLR) and outcome in Non Small Cell Lung Cancer (NSCLC) treated with Nivolumab or Docetaxel: a preliminary analysis.
2017-01-01 Russo, A; Scimone, A; Picciotto, M; Toscano, G; Raiti, F; Sava, S; Battaglia, A; Adamo, V.
Impact of maintenance Pemetrexed in the management of non-progressing malignant mesotheliomas after standard fist-line chemotherapy: a single institution experience.
2015-01-01 Franchina, T; Russo, A; Picone, A; Ricciardi, Grr; Raiti, F; Scimone, A; Chiofalo, G; Toscano, G; Adamo, V.
55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study.
2019-01-01 Nigro, O; Cortellini, A; Giusti, R; Marchetti, P; De Galitiis, F; Di Pietro, F; Bersanelli, M; Lazzarin, A; Galetta, D; Pizzutillo, P; Santini, D; Torniai, M; De Giglio, A; Russo, A; Silva, R; Bolzacchini, E; Natoli, C; Rijavec, E; Silva, R; Vallini, I; Pinotti, G.
Exosomal PD-L1 expression as non-invasive biomarker for immune checkpoint inhibitors in non-small cell lung cancer.
2020-01-01 Gunasekaran, M; Russo, A; Cardona, Af; De Miguel Perez, D; Lapidus, R; Cooper, B; Kaushal, S; Adamo, V; Rolfo, C.
Could EGFR Gene Mutations Provide a Selective Advantage to Malignant Cells in Specific Sites? New Perspectives in Lung Adenocarcinoma Biology.
2015-01-01 Franchina, T; Russo, A; Franchina, V; Picone, A; Ricciardi, Grr; Ferraro, G; Picciotto, M; Toscano, G; Adamo, V.
Impact of germline Methylenetetrahydrofolate Reductase (MTHFR) polymorphisms on Pemetrexed-based therapies In thoracic malignancies: a pilot study.
2014-01-01 Franchina, T; Russo, A; Picone, A; Ientile, R; Caccamo, D; Currò, M; Franchina, V; Chillari, F; Del Re, C; Ferraro, G; Picciotto, M; Toscano, G; Adamo, V.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Extracellular Vesicles Isolated From Bone Marrow Mesenchymal Stem Cells Induce An Anti-Inflammatory Phenotype In Microglia Exposed To Human Abeta 1-42 | 1-gen-2016 | Elia, Ca; Marchetti, S; Losurdo, M; Saccomano, A; Filipello, F; Rasile, M; Tamborini, M; Matteoli, M; Coco, S | |
| A Neuro-Vascular Unit in vitro model for drug screening of Blood Brain Barrier permeability and Immune Cells Trafficking | 1-gen-2023 | Lauranzano, E; Ravanelli, Mm; Rasile, M; Molteni, R; Faggiani, E; Liberatore, G; Pardi, R; Orazio, En; Matteoli, M | |
| Baseline markers of inflammation and outcome with Nivolumab in pretreated Non Small Cell Lung Cancers: a retrospective study. | 1-gen-2018 | Russo, A; Battaglia, A; Provazza, G; Lo Certo, G; Ricciardi, Grr; Picciotto, M; Scimone, A; Toscano, G; Adamo, V; Franchina, T. | |
| 31 Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients | 1-gen-2020 | De Miguel Perez, D; Russo, A; Gunasekaran, M; Cardona, A; Lapidus, R; Cooper, B; Et, Al. | |
| 117P Family history of cancer and improved outcomes with first-line immunotherapy in NSCLC patients. | 1-gen-2021 | Cortellini, A; Buti, S; Di Maio, M; Giusti, R; Nigro, O; Cantini, L; Bria, E; Grossi, F; Torniai, M; De Tursi, M; Citarella, F; Mazzoni, F; Gelibter, A; Macerelli, M; Migliorino, Mr; Russo, A; Addeo, A; Porzio, G; Ficorella, C; Pinato, Dj. | |
| New strategies to overcome BRAF resistance in melanoma: extended BRAF or BRAF/MEK inhibition? A pooled analysis. | 1-gen-2017 | Franchina, T; Raiti, F; Moretti, G; Zanghì, M; Ricciardi, Grr; Russo, A; Franchina, V; Adamo, V. | |
| Immune-Oncology Gene Expression Profiles allow lung cancer patients' stratification and identification of responders to immunotherapy. | 1-gen-2019 | Tabbò, F; Annaratone, L; Nocifora, A; Vignale, C; Carnio, S; Metovic, J; Veneziano, F; Scodes, S; Russo, A; Franchina, T; Sini, C; Coco, S; Garlatti, P; Scotti, V; Adamo, V; Boccardo, S; Grossi, F; Cappuzzo, F; Papotti, M; Righi, L; Passiglia, F; Novello, S. | |
| Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study. | 1-gen-2020 | Nigro, O; Pinotti, G; Giusti, R; Filetti, M; De Galitiis, F; Di Pietro, Fr; Bersanelli, M; Lazzarin, A; Catino, A; Pizzutillo, P; Russano, M; Torniai, M; Ricciuti, B; Russo, A; Tudini, M; Bolzacchini, E; Di Marino, P; Rijavec, E; Vallini, I; Ficorella, C; Cortellini, A. | |
| Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance | 1-gen-2013 | Franchina, T; Russo, A; Picciotto, M; Scimone, A; Berenato, R; Noto, L; Schifano, S; Adamo, V. | |
| Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis. | 1-gen-2018 | Giuffrida, D; Chillari, F; Blanco, G; Russo, A; Franchina, T; Puliafito, I; Prestifilippo, A; Battaglia, A; Castorina, L; Adamo, V. | |
| PO-063: Extracellular vesicle miRNAs and autophagic CTCs: Predictive and prognostic biomarkers in radiotherapy treated NSCLC patients. | 1-gen-2021 | De Miguel Perez, D; Tejada, Rg; Russo, A; Ortega, Fg; Martínez-Única, A; Gunasekaran, M; Lorente, Ja; Exposito, J; Fernandez, Mjs; Rolfo, C | |
| The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis | 1-gen-2015 | Bronte, G; Franchina, T; Alù, M; Sortino, G; Celesia, C; Passiglia, F; Savio, G; Laudani, A; Russo, A; Picone, A; Rizzo, S; Blasi, L; Adamo, V; Russo, A. | |
| Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non small cell lung cancer (NSCLC) | 1-gen-2019 | Russo, A; Franchina, T; Ricciardi, G; Battaglia, A; Schifano, S; Schifilliti, M; Scimone, A; Toscano, G; Zanghì, M; Adamo, V. | |
| The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lung cancer patients: Findings from a retrospective analysis. | 1-gen-2015 | Bronte, G; Franchina, T; Alù, M; Sortino, G; Celesia, C; Passiglia, F; Savio, G; Laudani, A; Russo, A; Picone, A; Rizzo, S; Blasi, L; Adamo, V; Russo, A. | |
| Baseline Absolute Neutrophil Count (ANC), derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Platelet-to-Lymphocyte Ratio (PLR) and outcome in Non Small Cell Lung Cancer (NSCLC) treated with Nivolumab or Docetaxel: a preliminary analysis. | 1-gen-2017 | Russo, A; Scimone, A; Picciotto, M; Toscano, G; Raiti, F; Sava, S; Battaglia, A; Adamo, V. | |
| Impact of maintenance Pemetrexed in the management of non-progressing malignant mesotheliomas after standard fist-line chemotherapy: a single institution experience. | 1-gen-2015 | Franchina, T; Russo, A; Picone, A; Ricciardi, Grr; Raiti, F; Scimone, A; Chiofalo, G; Toscano, G; Adamo, V. | |
| 55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study. | 1-gen-2019 | Nigro, O; Cortellini, A; Giusti, R; Marchetti, P; De Galitiis, F; Di Pietro, F; Bersanelli, M; Lazzarin, A; Galetta, D; Pizzutillo, P; Santini, D; Torniai, M; De Giglio, A; Russo, A; Silva, R; Bolzacchini, E; Natoli, C; Rijavec, E; Silva, R; Vallini, I; Pinotti, G. | |
| Exosomal PD-L1 expression as non-invasive biomarker for immune checkpoint inhibitors in non-small cell lung cancer. | 1-gen-2020 | Gunasekaran, M; Russo, A; Cardona, Af; De Miguel Perez, D; Lapidus, R; Cooper, B; Kaushal, S; Adamo, V; Rolfo, C. | |
| Could EGFR Gene Mutations Provide a Selective Advantage to Malignant Cells in Specific Sites? New Perspectives in Lung Adenocarcinoma Biology. | 1-gen-2015 | Franchina, T; Russo, A; Franchina, V; Picone, A; Ricciardi, Grr; Ferraro, G; Picciotto, M; Toscano, G; Adamo, V. | |
| Impact of germline Methylenetetrahydrofolate Reductase (MTHFR) polymorphisms on Pemetrexed-based therapies In thoracic malignancies: a pilot study. | 1-gen-2014 | Franchina, T; Russo, A; Picone, A; Ientile, R; Caccamo, D; Currò, M; Franchina, V; Chillari, F; Del Re, C; Ferraro, G; Picciotto, M; Toscano, G; Adamo, V. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista2015
Data di pubblicazione
- 2020 - 2025102
- 2010 - 20191267
- 2000 - 2009534
- 1990 - 1999111
- 1988 - 19891
Editore
- Nature Publishing Group4
- s.n4
- ICRS3
- Blackwell1
Rivista
- EUROPEAN UROLOGY. SUPPLEMENTS124
- GASTROENTEROLOGY121
- EUROPEAN JOURNAL OF NUCLEAR MEDIC...119
- THE JOURNAL OF UROLOGY110
- DIGESTIVE AND LIVER DISEASE96
- THE JOURNAL OF NUCLEAR MEDICINE80
- ANNALS OF THE RHEUMATIC DISEASES69
- RADIOTHERAPY AND ONCOLOGY58
- ANNALS OF ONCOLOGY55
- JOURNAL OF CLINICAL ONCOLOGY44
Keyword
- Myelodysplastic syndrome8
- Survival4
- biomimetic3
- Mitochondrial ferritin3
- osteochondral3
- Prognosis3
- scaffold3
- Sideroblastic anemia3
- viscosupplementation3
- COLONOSCOPIC SURVEILLANCE2
Lingua
- eng732
- ita24
- und6
Accesso al fulltext
- no fulltext1962
- reserved51
- open2